The Next Big Thing in Biotech: FDA Approvals
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
